PDCD1 and neoplasm: Four new approvals (2%) were in the tumor agnostic setting, including neurotrophic tyrosine receptor kinase inhibitors entrectinib and larotrectinib, both approved for patients with neurotrophic tyrosine receptor kinase variants who have no satisfactory alternative treatments, and 2 approvals for the anti–programmed cell death 1 drug pembrolizumab in cancers when patients have no satisfactory alternative treatment options and have either a high tumor variant burden or have high levels of microsatellite instability or mismatch repair deficiency.